Nasal spray delivers new type of depression treatment

March 24, 2014

A nasal spray that delivers a peptide to treat depression holds promise as a potential alternative therapeutic approach, research from the Centre for Addiction and Mental Health (CAMH) shows. The study, led by CAMH's Dr. Fang Liu, is published online in Neuropsychopharmacology.

In a previous study published in Nature Medicine in 2010, Dr. Liu developed a protein peptide that provided a highly targeted approach to treating that she hopes will have minimal side effects. The peptide was just as effective in relieving symptoms when compared to a conventional antidepressant in animal testing. However, the peptide had to be injected into the brain. Taken orally, it would not cross the blood-brain barrier in sufficient concentrations.

"Clinically, we needed to find a non-invasive, convenient method to deliver this peptide treatment," says Dr. Liu, Senior Scientist in the Campbell Family Mental Health Research Institute at CAMH. With the support of a Proof of Principle grant from the Canadian Institutes of Health Research (CIHR), Dr. Liu's team was able to further explore novel delivery methods.

The nasal delivery system, developed by U.S. company Impel NeuroPharma, was shown to deliver the peptide to the right part of the brain. It also relieved depression-like symptoms in animals.

"This study marks the first time a peptide treatment has been delivered through nasal passageways to treat depression," says Dr. Liu, Professor in the University of Toronto's Department of Psychiatry.

The peptide treatment interferes with the binding of two dopamine receptors – the D1 and D2 receptor complex. Dr. Liu's team had found that this binding was higher in the brains of people with major depression. Disrupting the binding led to the anti-depressant effects.

The peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters.

Depression, the most common form of mental illness, is one of the leading causes of disability globally. More than 50 per cent of people living with depression do not respond to first-line medication treatment.

"This research brings us one step closer to clinical trials," says Dr. Liu. In ongoing lab research, her team is experimenting to determine if they can make the peptide break down more slowly, and travel more quickly in the brain, to improve its anti-depressant effects.

Explore further: CAMH protein discovery may lead to new treatment to prevent smoking relapse

Related Stories

Recommended for you

Where belief in free will is linked to happiness

January 23, 2017

Western and Asian cultures tend to have different core beliefs around free will. In a recent study published in Frontiers in Psychology, Jingguang Li, professor at Dali University, and his research team show the link between ...

Study reveals areas of the brain impacted by PTSD

January 23, 2017

Researchers at Boston University School of Medicine (BUSM) and the VA Boston Healthcare System are one step closer to understanding the specific nature of brain changes associated with Posttraumatic Stress Disorder (PTSD).

For health and happiness, share good news

January 22, 2017

Service members, including both active and recently separated, have been called upon to fight overseas and to assist during natural disasters at home. They can face unique challenges when they return in both the workplace ...

The great unknown—risk-taking behaviour in adolescents

January 19, 2017

Adolescents are more likely to ignore information that could prompt them to rethink risky decisions. This may explain why information campaigns on risky behaviors such as drug abuse tend to have only limited success. These ...

Mandarin makes you more musical?

January 18, 2017

Mandarin makes you more musical - and at a much earlier age than previously thought. That's the suggestion of a new study from the University of California San Diego. But hold on there, overachiever parents, don't' rush just ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.